Editas Medicine, Inc.

EDITReported to SECin USCIK 0001650664Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 7. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 7
Form 4 lines at Editas Medicine, Inc., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Ory Daniel ScottEVP, Chief Medical OfficerAwardnothing paid950,000 sharesSep 9, 2026Ory Daniel ScottEVP, Chief Medical Officernothing paidAward · Sep 9Award950,000Sep 9, 2026
Parison AmySVP, Chief Financial OfficerOpen-market sell$1,376453 sharesSep 4, 2026Parison AmySVP, Chief Financial Officer$1,376Sell · Sep 4Open-market sell453Sep 4, 2026
Burkly LindaEVP, CHIEF SCIENTIFIC OFFICEROpen-market sell$2,153709 sharesSep 4, 2026Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER$2,153Sell · Sep 4Open-market sell709Sep 4, 2026
O'Neill Gilmore NeilCEOOpen-market sell$15,5635,124 sharesSep 4, 2026O'Neill Gilmore NeilCEO$15,563Sell · Sep 4Open-market sell5,124Sep 4, 2026
Ellinor Patrick Thomas II—Awardnothing paid103,400 sharesAug 7, 2026Ellinor Patrick Thomas IInothing paidAward · Aug 7Award103,400Aug 7, 2026